Skip to main content

Research Repository

See what's under the surface

Advanced Search

Strategy for tumor selective disruption of androgen receptor function in the spectrum of prostate cancer

Rosati, Rayna; Polin, Lisa A.; Ducker, Charles; Li, Jing; Bao, Xun; Selvakumar, Dakshnamurthy; Kim, Seongho; Xhabija, Besa; Larsen, Martha; McFall, Thomas; Huang, Yanfang; Kidder, Benjamin L.; Fribley, Andrew; Saxton, Janice; Kakuta, Hiroki; Shaw, Peter E.; Ratnam, Manohar

Authors

Rayna Rosati

Lisa A. Polin

Charles Ducker

Jing Li

Xun Bao

Dakshnamurthy Selvakumar

Seongho Kim

Besa Xhabija

Martha Larsen

Thomas McFall

Yanfang Huang

Benjamin L. Kidder

Andrew Fribley

Janice Saxton

Hiroki Kakuta

Peter E. Shaw

Manohar Ratnam



Abstract

Purpose: Testosterone suppression in prostate cancer (PC) is limited by serious side effects and resistance via restoration of androgen receptor (AR) functionality. ELK1 is required for ARdependent growth in various hormone-dependent and castration resistant PC models. The amino terminal domain of AR docks at two sites on ELK1 to co-activate essential growth genes. This study explores the ability of small molecules to disrupt the ELK1-AR interaction in the spectrum of PC, inhibiting AR activity in a manner that would predict functional tumor selectivity. Experimental design: Small molecule drug discovery and extensive biological characterization of a lead compound. Results: We have discovered a lead molecule (KCI807) that selectively disrupts ELK1-dependent promoter activation by wild-type and variant ARs without interfering with ELK1 activation by ERK. KCI807 has an obligatory flavone scaffold and functional hydroxyl groups on C5 and C3'. KCI807 binds to AR, blocking ELK1 binding, and selectively blocks recruitment of AR to chromatin by ELK1. KCI807 primarily affects a subset of AR target growth genes selectively suppressing AR-dependent growth of PC cell lines with a better inhibitory profile than enzalutamide. KCI807 also inhibits in vivo growth of castration/enzalutamide-resistant cell line-derived and patient-derived tumor xenografts. In the rodent model, KCI807 has a plasma half-life of 6h and maintenance of its antitumor effect is limited by self-induced metabolism at its 3'-hydroxyl. Conclusions: The results offer a mechanism-based therapeutic paradigm for disrupting the AR growth-promoting axis in the spectrum of prostate tumors while reducing global suppression of testosterone actions. KCI807 offers a good lead molecule for drug development.

Journal Article Type Article
Publication Date Sep 5, 2018
Journal Clinical Cancer Research
Print ISSN 1078-0432
Electronic ISSN 1557-3265
Publisher American Association for Cancer Research
Peer Reviewed Peer Reviewed
APA6 Citation Rosati, R., Polin, L. A., Ducker, C., Li, J., Bao, X., Selvakumar, D., …Ratnam, M. (2018). Strategy for tumor selective disruption of androgen receptor function in the spectrum of prostate cancer. Clinical Cancer Research, doi:10.1158/1078-0432.ccr-18-0982. ISSN 1078-0432
DOI https://doi.org/10.1158/1078-0432.ccr-18-0982
Keywords Prostate cancer; Castration resistance; Androgen receptor; ELK1; Drug discovery
Publisher URL http://clincancerres.aacrjournals.org/content/early/2018/09/05/1078-0432.CCR-18-0982

Files

Strategy for Tumor Selective Disruption of Androgen Receptor Function (310 Kb)
PDF


Strategy for Tumor Selective Disruption of Androgen Receptor Function (figures) (746 Kb)
PDF


Strategy for Tumor Selective Disruption of Androgen Receptor Function (supplementary figures) (957 Kb)
PDF


Strategy for Tumor Selective Disruption of Androgen Receptor (table) (94 Kb)
PDF


Strategy for Tumor Selective Disruption of Androgen Receptor Function (supplementary tables) (2.5 Mb)
PDF





You might also like



Downloadable Citations

;